Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

El-Khoueiry, Anthony B; Sarantopoulos, John; O'Bryant, Cindy L; Ciombor, Kristen K; Xu, Huiping; O'Gorman, Melissa; Chakrabarti, Jayeta; Usari, Tiziana; El-Rayes, Bassel F
April 2018
Cancer Chemotherapy & Pharmacology;Apr2018, Vol. 81 Issue 4, p659
Academic Journal
journal article
Purpose: This phase 1 study evaluated the effect of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.Methods: Patients were dosed according to hepatic function classified by modified National Cancer Institute Organ Dysfunction Working Group criteria and group assignment [normal (A1 and A2), mild (B), moderate (C1 and C2), or severe (D)]. Primary pharmacokinetic endpoints included area under the concentration-time curve as daily exposure (AUCdaily) and maximum plasma concentration (Cmax) at steady state. Safety endpoints included types, incidence, seriousness, and relationship to crizotinib of adverse events.Results: The AUCdaily and Cmax in patients with normal liver function were 7107 ng h/mL and 375.1 ng/mL (A1) and 5422 ng h/mL and 283.9 ng/mL (A2), respectively. The AUCdaily and Cmax ratios of adjusted geometric means for Groups B, C2, and D versus Group A1 were 91.12 and 91.20, 114.08 and 108.87, and 64.47 and 72.63, respectively. Any grade treatment-related adverse events (TRAEs) occurred in 75% of patients; grade 3/4 TRAEs occurred in 25%, including fatigue (6%), hyponatremia (5%), and hyperbilirubinemia (3%).Conclusions: No adjustment to the approved 250 mg twice daily (BID) dose of crizotinib is recommended for patients with mild hepatic impairment. The recommended dose is 200 mg BID for patients with moderate hepatic impairment, and the dose should not exceed 250 mg daily for patients with severe hepatic impairment. Adverse events appeared consistent among the hepatic impairment groups.Clinical Trial Registration No: NCT01576406.


Related Articles

  • White-matter hyperintensities in first-episode psychosis. Zanetti, Marcus V.; Schaufelberger, Maristela S.; De Castro, Cláudio C.; Menezes, Paulo R.; Scazufca, Márcia; McGuire, Philip K.; Murray, Robin M.; Busatto, Geraldo F.; de Castro, Cláudio C; Scazufca, Márcia // British Journal of Psychiatry;Jul2008, Vol. 193 Issue 1, p25 

    Background: White-matter hyperintensities have been associated with both schizophrenia and mood disorders, particularly bipolar disorder, but results are inconsistent across studies.Aims: To examine whether white-matter hyperintensities are a vulnerability marker for...

  • Low leucocyte myeloperoxidase activity in patients with multiple sclerosis. Ramsaransing, G.; Teelken, A.; Prokopenko, V.M.; Arutjunyan, A.V.; De Keyser, J. // Journal of Neurology, Neurosurgery & Psychiatry;Jul2003, Vol. 74 Issue 7, p953 

    The gene for myeloperoxidase (MPO) has been implicated in multiple sclerosis (MS). By measuring H(2)O(2) dependent oxidation of 3,3'5,5'-tetramethylbenzidine with spectrophotometry the authors investigated MPO activity in peripheral blood leucocytes from 42 patients with MS (12 with secondary...

  • Patients with Rosacea Have Increased Risk of Depression and Anxiety Disorders: A Danish Nationwide Cohort Study. Egeberg, alexander; Hansen, Peter Riis; Gislason, Gunnar Hilmar; Thyssen, Jacob Pontoppidan // Dermatology (10188665);Apr2016, Vol. 232 Issue 2, p208 

    Background: Rosacea is a chronic skin condition that affects self-esteem and quality of life. However, data on depression and anxiety in patients with rosacea are scarce.Objective: The aim of this study was to investigate the relationship between rosacea and new-onset...

  • Switching to lower tar cigarettes does not increase or decrease the likelihood of future quit attempts or cessation. Hyland, Andrew; Hughes, John R.; Farrelly, Matthew; Cummings, K. Michael // Nicotine & Tobacco Research;Oct2003, Vol. 5 Issue 5, p665 

    This study examined whether switching to low-tar cigarettes predicts future quit attempts or smoking cessation. Prior studies of whether switching to low-tar cigarettes increases or decreases cessation behavior have produced contradictory results. We believed a large, prospective...

  • Pain Persists in Many Patients Five Years After Removal of the Gallbladder: Observations From Two Randomized Controlled Trials of Symptomatic, Noncomplicated Gallstone Disease and Acute Cholecystitis Vetrhus, Morten; Berhane, Tewelde; Søreide, Odd; Søndenaa, Karl; Søreide, Odd; Søndenaa, Karl // Journal of Gastrointestinal Surgery;Jul2005, Vol. 9 Issue 6, p826 

    After removal of the gallbladder, pain may persist in some patients. To study this condition, 124 patients from two randomized trials, including those with symptomatic noncomplicated gallbladder stones (n = 90) and acute cholecystitis (n = 34), were interviewed, while 139 patients (90%) excluded...

  • A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts. Bigler, Jeannette; Boedigheimer, Michael; Schofield, James P. R.; Skipp, Paul J.; Corfield, Julie; Rowe, Anthony; Sousa, Ana R.; Timour, Martin; Twehues, Lori; Xuguang Hu; Roberts, Graham; Welcher, Andrew A.; Wen Yu; Lefaudeux, Diane; De Meulder, Bertrand; Auffray, Charles; Chung, Kian F.; Adcock, Ian M.; Sterk, Peter J.; Djukanović, Ratko // American Journal of Respiratory & Critical Care Medicine;5/15/2017, Vol. 195 Issue 10, p1311 

    Rationale: Stratification of asthma at the molecular level, especially using accessible biospecimens, could greatly enable patient selection for targeted therapy.Objectives: To determine the value of blood analysis to identify transcriptional differences between...

  • Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria. Brooks, Ellen R.; Hoppe, Bernd; Milliner, Dawn S.; Salido, Eduardo; Rim, John; Krevitt, Leah M.; Olson, Julie B.; Price, Heather E.; Vural, Gulsah; Langman, Craig B. // American Journal of Nephrology;Jun2016, Vol. 43 Issue 4, p293 

    Background: Primary hyperoxaluria type 1 (PH1) and idiopathic hypercalciuria (IHC) are stone-forming diseases that may result in the formation of calcium (Ca) oxalate (Ox) stones, nephrocalcinosis, and progressive chronic kidney disease (CKD). Poorer clinical outcome in PH1 is...

  • Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. Reuben, Adrian; Tillman, Holly; Fontana, Robert J.; Davern, Timothy; McGuire, Brendan; Stravitz, R. Todd; Durkalski, Valerie; Larson, Anne M.; Iris Liou; Fix, Oren; Schilsky, Michael; McCashland, Timothy; Hay, J. Eileen; Murray, Natalie; Shaikh, Obaid S.; Ganger, Daniel; Zaman, Atif; Han, Steven B.; Chung, Raymond T.; Smith, Alastair // Annals of Internal Medicine;6/7/2016, Vol. 164 Issue 11, p724 

    Background: Acute liver failure (ALF) is a rare syndrome of severe, rapid-onset hepatic dysfunction-without prior advanced liver disease-that is associated with high morbidity and mortality. Intensive care and liver transplantation provide support and rescue,...

  • The Predictive Values Of The Meld And Child-Pugh Scores In Determining Mortality From Chronic Liver Disease Patients In Anambra State, Nigeria. Okonkwo, U. C.; Nwosu, M. N.; Bojuwoye, B. J. // Internet Journal of Gastroenterology;2011, Vol. 10 Issue 2, p1 

    Background: Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide with differing aetiology in different geographic regions. The Child-Pugh's (C-P) and Model for end-stage liver disease (MELD) scores are important determinants of severity and prognosis in CLD. We aimed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics